Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: Findit who wrote (56405)	9/26/2006 3:21:06 PM
From: hotlinktuna	Respond to of 59879

Good luck Jim!! Some energy and energy related stocks higher today! tuna

To: Findit who wrote (56405)	9/27/2006 9:30:10 AM
From: hotlinktuna	Respond to of 59879

Hi Jim and all...watch VXGN 4.40 for possible upside again today after upward restatement of 2001/2002/2003 earnings and revs: bizjournals.com VaxGen restates results for three years Tuesday September 26, 1:36 pm ET Vaccine maker VaxGen Inc. filed its restated financial report for 2003 on Tuesday -- the first step toward getting its stock listed on the Nasdaq National Market exchange again. The Brisbane company (Pink Sheets: VXGN - News) restated results in the 2003 report for 2001, 2002 and 2003. Its fiscal year ends Dec. 31. The company decided to restate results because it deferred revenue in a way that wasn't appropriate under generally accepted accounting principles. VaxGen's investment in a South Korean subsidiary, Celltrion Inc., also complicated its accounting and financial reporting. VaxGen reported the following results: For 2003: Restated revenue of $29.1 million instead of $14.3 million; restated loss of $21.7 million instead of a loss of $28.7 million. For 2002: Restated revenue of $3.2 million instead of $1.6 million; restated loss of $54.7 million versus a loss of $49.8 million. For 2001: Revenue unchanged at $895,000; restated loss of $24.2 million versus a previously reported loss of $24.5 million. VaxGen was awarded an $877.5 million anthrax vaccine contract by the federal government, although the company's ability to meet the delivery requirements of that agreement has been questioned. The company still owns a minority stake in Celltrion. Published September 26, 2006 by San Francisco Business Times